UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form	6-K
L OI III	U-IN

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2012

Commission File Number: 001-34949

Tekmira Pharmaceuticals Corporation

(Translation of registrant's name into English)

100-8900 Glenlyon Parkway Burnaby, British Columbia Canada, V5J 5J8

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F R Form 40-F £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) £

DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Tekmira Pharmaceuticals Corporation

Date: June 27, 2012 By: <u>/s/ IAN C. MORTIMER</u>

Name: Ian C. Mortimer

Title: Executive Vice President, Finance and Chief Financial Officer

EXHIBIT INDEX

Exhibit 99.1 Description
Report of Voting Results

ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS OF TEKMIRA PHARMACEUTICALS CORPORATION (THE "COMPANY") HELD ON JUNE 20, 2012

REPORT OF VOTING RESULTS

National Instrument 51-102 – *Continuous Disclosure Obligations (Section 11.3)*

The following matters were put to a vote by a show of hands at the annual and special meeting of the Company:

Outcome of Vote 1. The election of the following nominees as directors of the Company for the ensuing year or Carried until their successors are elected or appointed: Michael Abrams Kenneth Galbraith Don Jewell Frank Karbe Daniel Kisner Mark J. Murray 2. The appointment of KPMG LLP as auditor of the Company for the ensuing year. Carried 3. Resolution of shareholders of the Company approving the amendment to the Company's Carried omnibus share compensation plan to increase from 1,643,144 to 2,193,870 common shares in respect of which awards may be granted thereunder.

DATED the 22nd day of June, 2012.

TEKMIRA PHARMACEUTICALS CORPORATION

By: /s/ R. Hector MacKay-Dunn
R. Hector MacKay-Dunn, Q.C.
Corporate Secretary